Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
CardiovascularORALGeneric

JUVISYNC

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

Standard Dose
40MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview JUVISYNC is listed in Drugs@FDA under application 202343 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient SIMVASTATIN; SITAGLIPTIN PHOSPHATE Form and strength TABLET;ORAL - 40MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor MERCK SHARP DOHME Submission history Latest submission status date: 2014-02-24 00:00:00.

Structured Monograph

Clinical summary

Approval overview JUVISYNC is listed in Drugs@FDA under application 202343 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient SIMVASTATIN; SITAGLIPTIN PHOSPHATE Form and strength TABLET;ORAL - 40MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor MERCK SHARP DOHME Submission history Latest submission status date: 2014-02-24 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.